417P New Insights into Second-Line (2L) Choices after CDK4/6 Inhibitors (cdk4/6i) in Hormone Receptor-Positive (HR+)/ Human Epidermal Growth Factor 2-Negative (HER2-) Metastatic Breast Cancer (MBC) Patients (pts): Preliminary Results of the HERMIONE-13 Study
Annals of Oncology（2023）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined